{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:00:28Z","timestamp":1782828028498,"version":"3.54.5"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2019JQ-252"],"award-info":[{"award-number":["2019JQ-252"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2019JQ-484"],"award-info":[{"award-number":["2019JQ-484"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2019JQ-779"],"award-info":[{"award-number":["2019JQ-779"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2020CGXNG-044"],"award-info":[{"award-number":["2020CGXNG-044"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602967"],"award-info":[{"award-number":["81602967"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803784"],"award-info":[{"award-number":["81803784"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003699"],"award-info":[{"award-number":["82003699"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2016M592898XB"],"award-info":[{"award-number":["2016M592898XB"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019M663921XB"],"award-info":[{"award-number":["2019M663921XB"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020MH141"],"award-info":[{"award-number":["ZR2020MH141"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009103","name":"Education Department of Shaanxi Province","doi-asserted-by":"publisher","award":["19JC006"],"award-info":[{"award-number":["19JC006"]}],"id":[{"id":"10.13039\/501100009103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.biopha.2022.112894","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T07:58:55Z","timestamp":1648799935000},"page":"112894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)"],"prefix":"10.1016","volume":"149","author":[{"given":"Juan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyuan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112894_bib1","series-title":"Heart Failure in the Child and Young Adult","first-page":"3","article-title":"Molecular and cellular mechanisms in heart failure","author":"Puggia","year":"2018"},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.112894_bib3","unstructured":"National Clinical Guideline, National Institute for Health and Clinical Excellence: Guidance, Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update, Royal College of Physicians (UK)Copyright \u00a9 2010, National Clinical Guideline Centre, London, 2010."},{"issue":"8","key":"10.1016\/j.biopha.2022.112894_bib4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.biopha.2022.112894_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehaa1061","article-title":"The year in cardiovascular medicine 2020: heart failure and cardiomyopathies","volume":"42","author":"Bueno","year":"2021","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCHEARTFAILURE.112.972828","article-title":"Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction","volume":"6","author":"Ho","year":"2013","journal-title":"Circ. Heart Fail."},{"issue":"1","key":"10.1016\/j.biopha.2022.112894_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ejhf.1227","article-title":"Heart failure with preserved ejection fraction in Asia","volume":"21","author":"Tromp","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"10.1016\/j.biopha.2022.112894_bib8","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/ejhf.1350","article-title":"Risk factors for incident heart failure in age- and sex-specific strata: a population-based cohort using linked electronic health records","volume":"21","author":"Uijl","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2022.112894_bib9","first-page":"237","article-title":"The causes, consequences, and treatment of left or right heart failure","volume":"7","author":"Pazos-L\u00f3pez","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"issue":"6","key":"10.1016\/j.biopha.2022.112894_bib10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.21037\/atm-20-4600","article-title":"Optimal diuretic strategies in heart failure","volume":"9","author":"Suri","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"3","key":"10.1016\/j.biopha.2022.112894_bib11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","article-title":"The annual global economic burden of heart failure","volume":"171","author":"Cook","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/HCO.0000000000000594","article-title":"Update on the diagnosis and management of acute heart failure","volume":"34","author":"Gouda","year":"2019","journal-title":"Curr. Opin. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2022.112894_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.31083\/j.rcm.2020.04.154","article-title":"Epidemiology and pathogenesis of heart failure with preserved ejection fraction","volume":"21","author":"Nair","year":"2020","journal-title":"Rev. Cardiovasc. Med."},{"issue":"10)","key":"10.1016\/j.biopha.2022.112894_bib14","first-page":"56","article-title":"Heart Disease and Stroke Statistics-2019 Update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.biopha.2022.112894_bib15","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1093\/eurheartj\/ehv565","article-title":"Improving outcomes in heart failure: a personal perspective","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.biopha.2022.112894_bib16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail"},{"issue":"6","key":"10.1016\/j.biopha.2022.112894_bib17","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.biopha.2022.112894_bib18","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"10.1016\/j.biopha.2022.112894_bib19","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"10244","key":"10.1016\/j.biopha.2022.112894_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2022.112894_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"10.1016\/j.biopha.2022.112894_bib22","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2022.112894_bib23","unstructured":"Drug Trials Snapshot: VERQUVO. February 08, 2021. \u3008https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshot-verquvo\u3009. (Accessed July 2021)."},{"key":"10.1016\/j.biopha.2022.112894_bib24","first-page":"1","article-title":"Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options","author":"Hulot","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/FJC.0000000000000724","article-title":"Multiplicity of nitric oxide and natriuretic peptide signaling in heart failure","volume":"75","author":"Preedy","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2022.112894_bib26","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11897-016-0290-z","article-title":"Soluble guanylate cyclase stimulators: a novel treatment option for heart failure associated with cardiorenal syndromes?","volume":"13","author":"Dubin","year":"2016","journal-title":"Curr. Heart Fail. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2022.112894_bib27","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.109.895235","article-title":"Aldosterone receptor antagonists","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.biopha.2022.112894_bib28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1526-4610.2009.01342.x","article-title":"Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and an update","volume":"49","author":"Tfelt-Hansen","year":"2009","journal-title":"Headache"},{"issue":"1","key":"10.1016\/j.biopha.2022.112894_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2022.112894_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1515\/hsz-2018-0155","article-title":"From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators","volume":"399","author":"Sandner","year":"2018","journal-title":"Biol. Chem."},{"issue":"24","key":"10.1016\/j.biopha.2022.112894_bib31","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1111\/bph.14920","article-title":"Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease","volume":"177","author":"Tzoumas","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"18","key":"10.1016\/j.biopha.2022.112894_bib32","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2174\/1389557519666190730110600","article-title":"Soluble guanylate cyclase stimulators and activators: where are we and where to go?","volume":"19","author":"Xiao","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2022.112894_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/13543776.2021.1866538","article-title":"Soluble guanylate cyclase stimulators and their potential use: a patent review","volume":"31","author":"Sandner","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.biopha.2022.112894_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/164_2016_100","article-title":"Novel sGC stimulators and sGC activators for the treatment of heart failure","volume":"243","author":"Breitenstein","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"issue":"6825","key":"10.1016\/j.biopha.2022.112894_bib35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.biopha.2022.112894_bib36","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMe2006855","article-title":"Vericiguat - another victory for targeting cyclic GMP in heart failure","volume":"382","author":"Burnett","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00210-019-01779-z","article-title":"cGMP: a unique 2nd messenger molecule - recent developments in cGMP research and development","volume":"393","author":"Friebe","year":"2020","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112894_bib38","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-642-38664-0_12","article-title":"Soluble guanylate cyclase stimulators in pulmonary hypertension","volume":"218","author":"Stasch","year":"2013","journal-title":"Handb. Exp. Pharmacol."},{"issue":"5701","key":"10.1016\/j.biopha.2022.112894_bib39","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.1103596","article-title":"Femtomolar sensitivity of a NO sensor from Clostridium botulinum","volume":"306","author":"Nioche","year":"2004","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.biopha.2022.112894_bib40","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.str.2009.08.011","article-title":"Structure and signaling mechanism of Per-ARNT-Sim domains","volume":"17","author":"M\u00f6glich","year":"2009","journal-title":"Structure"},{"issue":"25","key":"10.1016\/j.biopha.2022.112894_bib41","doi-asserted-by":"crossref","first-page":"13414","DOI":"10.1073\/pnas.94.25.13414","article-title":"Catalytic mechanism of the adenylyl and guanylyl cyclases: modeling and mutational analysis","volume":"94","author":"Liu","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.biopha.2022.112894_bib42","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/pro.2331","article-title":"Crystal structure of the Alpha subunit PAS domain from soluble guanylyl cyclase","volume":"22","author":"Purohit","year":"2013","journal-title":"Protein Sci."},{"key":"10.1016\/j.biopha.2022.112894_bib43","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50634","article-title":"Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy","volume":"8","author":"Horst","year":"2019","journal-title":"eLife"},{"issue":"11","key":"10.1016\/j.biopha.2022.112894_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044481","article-title":"The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy","volume":"7","author":"Irvine","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib45","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.HYP.0000241087.12492.47","article-title":"Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats","volume":"48","author":"Masuyama","year":"2006","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.biopha.2022.112894_bib46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/hr.2009.64","article-title":"Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart","volume":"32","author":"Masuyama","year":"2009","journal-title":"Hypertens. Res."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/cvr\/cvt257","article-title":"NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size","volume":"101","author":"Bice","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"12","key":"10.1016\/j.biopha.2022.112894_bib48","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1182\/blood.V84.12.4226.bloodjournal84124226","article-title":"YC-1, a novel activator of platelet guanylate cyclase","volume":"84","author":"Ko","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.112894_bib49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","article-title":"NO-independent, haem-dependent soluble guanylate cyclase stimulators","volume":"191","author":"Stasch","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2022.112894_bib50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bjp.0700982","article-title":"Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators","volume":"120","author":"M\u00fclsch","year":"1997","journal-title":"Br. J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2022.112894_bib51","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1038\/s41467-021-25617-0","article-title":"Activation mechanism of human soluble guanylate cyclase by stimulators and activators","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.biopha.2022.112894_bib52","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1002\/j.1460-2075.1996.tb01078.x","article-title":"Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme","volume":"15","author":"Friebe","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2022.112894_bib53","series-title":"Reactive Oxygen Species: Network Pharmacology and Therapeutic Applications","first-page":"355","article-title":"Soluble guanylate cyclase stimulators and activators","author":"Sandner","year":"2021"},{"issue":"1","key":"10.1016\/j.biopha.2022.112894_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjp.0702495","article-title":"Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity","volume":"127","author":"Galle","year":"1999","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2022.112894_bib55","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.biopha.2022.112894_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1254\/jphs.94.19","article-title":"YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits the spontaneous contractions of isolated pregnant rat myometrium","volume":"94","author":"Cetin","year":"2004","journal-title":"J. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2022.112894_bib57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/jm001034k","article-title":"Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase","volume":"44","author":"Selwood","year":"2001","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1254\/jphs.FPJ06017X","article-title":"Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator","volume":"102","author":"Nakane","year":"2006","journal-title":"J. Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2022.112894_bib59","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1515\/CCLM.2003.131","article-title":"Soluble guanylyl cyclase: physiological role as an NO receptor and the potential molecular target for therapeutic application","volume":"41","author":"Nakane","year":"2003","journal-title":"Clin. Chem. Lab. Med."},{"issue":"9","key":"10.1016\/j.biopha.2022.112894_bib60","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0024-3205(02)02361-5","article-title":"A-350619: a novel activator of soluble guanylyl cyclase","volume":"72","author":"Miller","year":"2003","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib61","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)64009-8","article-title":"BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro","volume":"169","author":"Kalsi","year":"2003","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib62","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bmcl.2013.01.028","article-title":"Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators","volume":"23","author":"Griebenow","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib63","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/cmdc.200900014","article-title":"Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension","volume":"4","author":"Mittendorf","year":"2009","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.biopha.2022.112894_bib64","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1161\/01.CIR.0000142209.28862.12","article-title":"Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition","volume":"110","author":"Bischoff","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/acsmedchemlett.5b00479","article-title":"Discovery of IWP-051, a novel orally bioavailable sgc stimulator with once-daily dosing potential in humans","volume":"7","author":"Nakai","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.bjp.0704484","article-title":"Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies","volume":"135","author":"Stasch","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"20","key":"10.1016\/j.biopha.2022.112894_bib67","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.112894_bib68","first-page":"39","article-title":"Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences","volume":"22","author":"Andersen","year":"2017","journal-title":"Respir. Med. Case Rep."},{"key":"10.1016\/j.biopha.2022.112894_bib69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejmech.2019.04.014","article-title":"Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension","volume":"173","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.biopha.2022.112894_bib70","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0091270008319793","article-title":"Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers","volume":"48","author":"Frey","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2022.112894_bib71","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ab.2004.12.025","article-title":"A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide\/cGMP pathway","volume":"339","author":"Wunder","year":"2005","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib72","first-page":"133","article-title":"Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization, Jpn.","volume":"37","author":"Inoue","year":"1992","journal-title":"J. Hum. Genet."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2022.112894_bib73","first-page":"S49","article-title":"Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam","volume":"6","author":"Becker","year":"2016","journal-title":"Pulm. Circ."},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib74","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40262-015-0337-4","article-title":"Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in healthy young Chinese male non-smokers and smokers: results of a Randomized, Double-Blind, Placebo-Controlled Study","volume":"55","author":"Zhao","year":"2016","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.biopha.2022.112894_bib75","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/004982598238868","article-title":"Molecular genetics of the human cytochrome P450 monooxygenase superfamily","volume":"28","author":"Smith","year":"1998","journal-title":"Xenobiotica"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2022.112894_bib76","first-page":"S15","article-title":"Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)","volume":"6","author":"Frey","year":"2016","journal-title":"Pulm. Circ."},{"issue":"48","key":"10.1016\/j.biopha.2022.112894_bib77","doi-asserted-by":"crossref","first-page":"9052","DOI":"10.1002\/anie.200907155","article-title":"Oxetanes as versatile elements in drug discovery and synthesis","volume":"49","author":"Burkhard","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"8","key":"10.1016\/j.biopha.2022.112894_bib78","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1021\/jm9018788","article-title":"Oxetanes in drug discovery: structural and synthetic insights","volume":"53","author":"Wuitschik","year":"2010","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.biopha.2022.112894_bib79","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acsmedchemlett.5b00157","article-title":"Molecular property design: does everyone get it?","volume":"6","author":"Leeson","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.biopha.2022.112894_bib80","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.112894_bib81","unstructured":"P.S.E. Johannes, M.B., Hubert, T. Herbert, H., Use of Stimulators and Activators of Soluble Guanylate Cyclase for Treating Sickle-cell Anemia Andconserving Blood Substitutes, WO 2011161099,\u00a0(2011)."},{"key":"10.1016\/j.biopha.2022.112894_bib82","unstructured":"F.J. Markus, P.S. Gorden, R. Jens, A. Nils, G. Walter, K. Andreas, K. Eva, M. B. Frank, W. Volkhart, M. L. Elke, H. Joachim, M. Karl, H. S. Rolf, J. Donald, B., Substituted 5-Fluoro-1h-Pyrazolopyridinesand Use Thereof, WO 2011147809,\u00a0(2011)."},{"issue":"3","key":"10.1016\/j.biopha.2022.112894_bib83","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/hlca.19510340311","article-title":"\u00dcber einige Derivate des Triazolo\u2010pyrimidins","volume":"34","author":"Bitterli","year":"1951","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.biopha.2022.112894_bib84","unstructured":"F.S. Peter, P.; Christian,F.; Natalya,P.K.; Olexandr,I.G.; Yuriy,G.S., Process for Manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine, WO 2020152010, (2020)."},{"key":"10.1016\/j.biopha.2022.112894_bib85","unstructured":"F. Peter, Method for Producing Substituted 5-Fluoro-1h-Pyrazolopyridines, WO 2013076168, (2013)."},{"key":"10.1016\/j.biopha.2022.112894_bib86","unstructured":"S. Alexander, F. Achim, A. Cristina, P.S. Johannes, P. Elisabeth, H. Joachim, D. Klaus, S. Elke, SubstituteD Pyrazole Derivatives Condensed with Six-membered Heterocyclic Rings, WO 2000006569, (2000)."},{"issue":"36","key":"10.1016\/j.biopha.2022.112894_bib87","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1002\/anie.201302588","article-title":"The chemistry and biology of soluble guanylate cyclase stimulators and activators","volume":"52","author":"Follmann","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2022.112894_bib88","unstructured":"W.J.-P.S. Markus Follmann, Solingen; Gorden Redlich, Bochum; Jens Ackerstaff, D\u00fcsseldorf; Nils Griebenow, Dormagen; Walter Kroh, Wuppertal; Andreas Knorr, Erkrath; Eva-Maria Becker, Wuppertal; Frank Wunder, Wuppertal; Volkhart Min-Jian Li, Velbert; Elke Hartmann, Wuppertal; Joachim Mittendorf, Wuppertal; Karl-Heinz Schlemmer, Wuppertal; Rolf Jautelat, Haan; Donald Bierer, Haan Substituted 5-Fluoro-1H-Pyrazolopyridines and their Use, USOO8921377B2, (2014)."},{"key":"10.1016\/j.biopha.2022.112894_bib89","unstructured":"P.G. Fey, Alfons;Bierer, Donald Method for Producing Substituted 5-Fluoro-1H-Pyrazolopyridines, AU2019202123B2, (2019)."},{"issue":"11","key":"10.1016\/j.biopha.2022.112894_bib90","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1021\/ol900716q","article-title":"A general and convenient catalytic synthesis of nitriles from amides and silanes","volume":"11","author":"Zhou","year":"2009","journal-title":"Org. Lett."},{"issue":"73","key":"10.1016\/j.biopha.2022.112894_bib91","doi-asserted-by":"crossref","first-page":"9204","DOI":"10.1039\/D1CC03537A","article-title":"Hydrosilylative reduction of primary amides to primary amines catalyzed by a terminal [Ni-OH] complex","volume":"57","author":"Pandey","year":"2021","journal-title":"Chem. Commun."},{"key":"10.1016\/j.biopha.2022.112894_bib92","unstructured":"W. Gu, Z. Dong, R. Wang, Compound for Adjusting Activity of NMDA Receptor, and Pharmaceutical Composition and Use Thereof, Beijing Greatway Pharmaceutica lTechnology Co., Ltd., Peop. Rep. China . 2021, 147."},{"issue":"8","key":"10.1016\/j.biopha.2022.112894_bib93","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models","volume":"28","author":"Sharkovska","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2022.112894_bib94","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","article-title":"Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"21","author":"Stasch","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2022.112894_bib95","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40265-021-01496-z","article-title":"Vericiguat: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2022.112894_bib96","first-page":"S66","article-title":"Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food","volume":"6","author":"Saleh","year":"2016","journal-title":"Pulm. Circ."},{"issue":"4","key":"10.1016\/j.biopha.2022.112894_bib97","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-020-03023-7","article-title":"Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects","volume":"77","author":"Boettcher","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"21","key":"10.1016\/j.biopha.2022.112894_bib98","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED Randomized Trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.112894_bib99","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-021-01024-y","article-title":"Population Pharmacokinetics and pharmacodynamics of vericiguat in patients with heart failure and reduced ejection fraction","author":"Ruehs","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"15","key":"10.1016\/j.biopha.2022.112894_bib100","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur. Heart J."},{"issue":"15","key":"10.1016\/j.biopha.2022.112894_bib101","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF Randomized Clinical Trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib102","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.005998","article-title":"Rationale and design of the VITALITY-HFpEF Trial","volume":"12","author":"Butler","year":"2019","journal-title":"Circ. Heart Fail."},{"issue":"20","key":"10.1016\/j.biopha.2022.112894_bib103","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib104","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA Trial,","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail."},{"issue":"4","key":"10.1016\/j.biopha.2022.112894_bib105","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ejhf.1778","article-title":"Vericiguat for heart failure and the VICTORIA trial - the dog that didn't bark?","volume":"22","author":"Coats","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"6","key":"10.1016\/j.biopha.2022.112894_bib106","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41569-020-0382-z","article-title":"Novel sGC stimulator improves outcomes in patients with HFrEF","volume":"17","author":"Huynh","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"suppl_1","key":"10.1016\/j.biopha.2022.112894_bib107","volume":"136","author":"Duengen","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.biopha.2022.112894_bib108","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-020-00895-x","article-title":"Metabolism and pharmacokinetic drug-drug interaction profile of vericiguat, a soluble guanylate cyclase stimulator: results from preclinical and phase i healthy volunteer studies","volume":"59","author":"Boettcher","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib109","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4155\/bio.14.257","article-title":"Determination of riociguat and its major human metabolite M-1 in human plasma by stable-isotope dilution LCMS\/MS","volume":"7","author":"Gnoth","year":"2015","journal-title":"Bioanalysis"},{"issue":"6","key":"10.1016\/j.biopha.2022.112894_bib110","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40262-017-0604-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of riociguat","volume":"57","author":"Frey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib111","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jmb.2007.03.066","article-title":"Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7","volume":"369","author":"Miley","year":"2007","journal-title":"J. Mol. Biol."},{"issue":"8","key":"10.1016\/j.biopha.2022.112894_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/toxins11080433","article-title":"Characterization of phase i and glucuronide phase ii metabolites of 17 mycotoxins using liquid chromatography-high-resolution mass spectrometry","volume":"11","author":"Slobodchikova","year":"2019","journal-title":"Toxins"},{"issue":"2","key":"10.1016\/j.biopha.2022.112894_bib113","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.dmpk.2019.01.005","article-title":"Establishment of rat liver microsome-hydrogel system for in vitro phase II metabolism and its application to study pharmacological effects of UGT substrates","volume":"34","author":"Zhang","year":"2019","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib114","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cbic.200301023","article-title":"Fluorine in medicinal chemistry","volume":"5","author":"B\u00f6hm","year":"2004","journal-title":"ChemBioChem"},{"issue":"5","key":"10.1016\/j.biopha.2022.112894_bib115","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14756360701425014","article-title":"The role of fluorine in medicinal chemistry","volume":"22","author":"Shah","year":"2007","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2022.112894_bib116","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40262-020-00935-6","article-title":"Pharmacodynamic and pharmacokinetic interaction profile of vericiguat: results from three randomized phase i studies in healthy volunteers","volume":"60","author":"Boettcher","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.biopha.2022.112894_bib117","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2022.112894_bib118","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1093\/cvr\/cvaa247","article-title":"Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial","volume":"116","author":"Lang","year":"2020","journal-title":"Cardiovasc. Res"},{"key":"10.1016\/j.biopha.2022.112894_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2221","article-title":"Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial","author":"Voors","year":"2021","journal-title":"Eur. J. Heart Fail."},{"issue":"41","key":"10.1016\/j.biopha.2022.112894_bib120","article-title":"The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure: a systematic review and meta-analysis","volume":"97","author":"Zheng","year":"2018","journal-title":"Med. (Baltim. )"},{"issue":"8","key":"10.1016\/j.biopha.2022.112894_bib121","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/ejhf.936","article-title":"August 2017 at a glance: tailored treatment, acute heart failure and cardiac resynchronization","volume":"19","author":"Metra","year":"2017","journal-title":"Eur. J. Heart Fail."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222002839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222002839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:19:50Z","timestamp":1774250390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222002839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":121,"alternative-id":["S0753332222002839"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112894","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF)","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112894","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112894"}}